Zura Bio Limited Class A Ordinary Shares (ZURA)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $119.44M
Last updated: Nov 17, 2026 at 11:06 AM ET
Zura Bio Limited Class A Ordinary Shares (ZURA) Stock Forecast
Analysts expect Zura Bio Limited Class A Ordinary Shares (ZURA) to earn -$0.80 per share in the fiscal year ending Dec 31, 2026. Of 7 analysts, 7 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 3 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 7 ratings average 1.86, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 1 | 14.3% |
| Buy | 6 | 85.7% |
| Hold | 0 | 0.0% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 7
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus shows a smaller loss.
- Fiscal year ending Dec 31, 2026
- -$0.80
- EPS consensus
- Fiscal year ending Dec 31, 2027
- -$0.69
- EPS consensus
- Next report
- Mar 17, 2027
- Estimated
EPS range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.80 | -$0.86 to -$0.64 | 5 |
| Dec 31, 2027 | -$0.69 | -$0.99 to -$0.42 | 5 |
Quarterly Estimates
The EPS consensus is -$0.20 for both quarters below, ending Dec 31, 2026 and Mar 31, 2027.
EPS range
| Quarter ending | EPS consensus | EPS range | EPS analysts |
|---|---|---|---|
| Dec 31, 2026 | -$0.20 | -$0.23 to -$0.16 | 10 |
| Mar 31, 2027 | -$0.20 | -$0.25 to -$0.18 | 3 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 7 upward and 1 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 3 | 0 |
| Fiscal year ending Dec 31, 2027 | 2 | 1 |
| Quarter ending Mar 31, 2027 | 2 | 0 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has improved from -$0.81.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | -$0.80 | -$0.79 | -$0.80 | -$0.81 | -$0.81 | N/A |
| Fiscal year ending Dec 31, 2027 | -$0.69 | -$0.68 | -$0.69 | -$0.69 | -$0.69 | N/A |
| Quarter ending Mar 31, 2027 | -$0.20 | -$0.20 | -$0.22 | -$0.22 | -$0.22 | N/A |
Frequently Asked Questions About ZURA
What is the ZURA stock forecast?
Consensus analyst estimates put Zura Bio Limited Class A Ordinary Shares's EPS at -$0.80 for the fiscal year ending Dec 31, 2026. The consensus rating from 7 analysts is Buy.
How do analysts rate ZURA stock?
Of 7 analysts covering Zura Bio Limited Class A Ordinary Shares, 1 rates it Strong Buy, 6 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from ZURA next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$0.80, with estimates from -$0.86 to -$0.64 from 5 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$0.69, with estimates from -$0.99 to -$0.42 from 5 analysts.
How many analysts cover ZURA?
7 analysts rate Zura Bio Limited Class A Ordinary Shares stock, and 5 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
ZURA pages: Overview, Earnings, Forecast, Financials, Competitors